Cargando…
Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
BACKGROUND: Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans. OBJECTIVE: The aim of this study was to characterize trends in s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611121/ https://www.ncbi.nlm.nih.gov/pubmed/34109569 http://dx.doi.org/10.1007/s41669-021-00274-7 |
_version_ | 1784603236975509504 |
---|---|
author | Corelli, Robin L. Tu, Thanh G. Lee, Kyoung J. Dinh, Drake Gericke, Kristin R. Hudmon, Karen Suchanek |
author_facet | Corelli, Robin L. Tu, Thanh G. Lee, Kyoung J. Dinh, Drake Gericke, Kristin R. Hudmon, Karen Suchanek |
author_sort | Corelli, Robin L. |
collection | PubMed |
description | BACKGROUND: Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans. OBJECTIVE: The aim of this study was to characterize trends in smoking cessation medication utilization between 2006 and 2017 within a Medicaid population and estimate per-member per-month (PMPM) costs to the health plan. METHODS: This study was a retrospective longitudinal analysis conducted among adult members of a Medicaid managed care plan in California. Pharmacy claims data from January 1, 2006 to December 31, 2017 were analyzed to estimate utilization and cost of smoking cessation medications. Additionally, data from 3164 members who filled prescription(s) for cessation medication(s) in 2017 were evaluated to quantify quit attempts and use of combination therapy. For members who had been prescribed bupropion SR, varenicline, or the nicotine patch, the extent to which the durations of therapy were consistent with the manufacturers’ recommended minimum duration of therapy were also assessed. RESULTS: The average PMPM expenditures for smoking cessation medications were approximately US$0.15 in 2017, compared with US$0.01–US$0.03 between 2006 and 2013. In 2017, a total of 3164 members initiated an estimated 3850 quit attempts, most commonly using the nicotine patch (57.5%) or varenicline (32.8%). Combination therapy accounted for 2.9% of quit attempts. The median therapy duration for the nicotine patch, varenicline, and bupropion SR was 28, 30, and 33 days, respectively, and for each of these medications, fewer than half of members filled prescriptions for the minimum recommended duration of therapy. CONCLUSIONS: Pharmacy claims data suggest that despite comprehensive coverage, most beneficiaries are underutilizing smoking cessation agents and are not completing the recommended treatment durations. |
format | Online Article Text |
id | pubmed-8611121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-86111212021-12-10 Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan Corelli, Robin L. Tu, Thanh G. Lee, Kyoung J. Dinh, Drake Gericke, Kristin R. Hudmon, Karen Suchanek Pharmacoecon Open Original Research Article BACKGROUND: Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans. OBJECTIVE: The aim of this study was to characterize trends in smoking cessation medication utilization between 2006 and 2017 within a Medicaid population and estimate per-member per-month (PMPM) costs to the health plan. METHODS: This study was a retrospective longitudinal analysis conducted among adult members of a Medicaid managed care plan in California. Pharmacy claims data from January 1, 2006 to December 31, 2017 were analyzed to estimate utilization and cost of smoking cessation medications. Additionally, data from 3164 members who filled prescription(s) for cessation medication(s) in 2017 were evaluated to quantify quit attempts and use of combination therapy. For members who had been prescribed bupropion SR, varenicline, or the nicotine patch, the extent to which the durations of therapy were consistent with the manufacturers’ recommended minimum duration of therapy were also assessed. RESULTS: The average PMPM expenditures for smoking cessation medications were approximately US$0.15 in 2017, compared with US$0.01–US$0.03 between 2006 and 2013. In 2017, a total of 3164 members initiated an estimated 3850 quit attempts, most commonly using the nicotine patch (57.5%) or varenicline (32.8%). Combination therapy accounted for 2.9% of quit attempts. The median therapy duration for the nicotine patch, varenicline, and bupropion SR was 28, 30, and 33 days, respectively, and for each of these medications, fewer than half of members filled prescriptions for the minimum recommended duration of therapy. CONCLUSIONS: Pharmacy claims data suggest that despite comprehensive coverage, most beneficiaries are underutilizing smoking cessation agents and are not completing the recommended treatment durations. Springer International Publishing 2021-06-09 /pmc/articles/PMC8611121/ /pubmed/34109569 http://dx.doi.org/10.1007/s41669-021-00274-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Corelli, Robin L. Tu, Thanh G. Lee, Kyoung J. Dinh, Drake Gericke, Kristin R. Hudmon, Karen Suchanek Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan |
title | Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan |
title_full | Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan |
title_fullStr | Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan |
title_full_unstemmed | Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan |
title_short | Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan |
title_sort | smoking cessation pharmacotherapy utilization and costs to a medicaid managed care plan |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611121/ https://www.ncbi.nlm.nih.gov/pubmed/34109569 http://dx.doi.org/10.1007/s41669-021-00274-7 |
work_keys_str_mv | AT corellirobinl smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan AT tuthanhg smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan AT leekyoungj smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan AT dinhdrake smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan AT gerickekristinr smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan AT hudmonkarensuchanek smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan |